BCI & Neuroscience — Timeline

Timeline

2004 — [Research] BrainGate first human trial — intracortical BCI enables cursor control for a paralyzed patient. Establishes the field of invasive motor BCI. (Context: Neuroprosthetics)
2016 — [Industry] Synchron founded, begins developing Stentrode endovascular BCI. (Context: Synchron)
2019 — [Industry] Neuralink reveals N1 implant design — 1,024 electrode threads with custom surgical robot for precision insertion. (Context: Neuralink)

2021 — [Clinical] Synchron Stentrode first-in-human implant — endovascular BCI delivered through jugular vein without craniotomy. (Context: Invasive vs. Non-Invasive BCI)
2022 — [Clinical] Synchron demonstrates iPad control through thought — patient sends messages and browses web using Stentrode. (Context: Synchron)
2023 — [Regulatory] Neuralink receives FDA approval for first human clinical trial (PRIME study). (Context: Neuralink)

2024 — [Clinical] Neuralink PRIME study begins — first patients receive N1 implant, demonstrate thought-controlled cursor and typing. (Context: Neuralink)
2024 — [Regulatory] FDA grants Neuralink breakthrough device designation for N1 implant. (Context: Neuralink)
2024 — [Research] Deep learning approaches achieve 10-20% accuracy improvement over traditional methods for EEG motor imagery classification. (Context: Neural Signal Decoding)

2025 — [Research] Flexible bioelectronics advance — conformal electrode arrays that follow skin contours improve non-invasive signal quality. (Context: Neural Signal Decoding)
2025 — [Clinical] Neuralink PRIME study expands, approaching 20 patients implanted. (Context: Neuralink)
Aug 2025 — [Technical Report] Stanford researchers decode inner speech from motor cortex microelectrode arrays — 4 patients with severe paralysis. Key finding: inner speech patterns are attenuated versions of attempted speech patterns. (Stanford Inner Speech)

(Newest first. Mid-2026 wave added in the Jun 2026 ingest; earlier-2026 entries follow.)

Jun 17 — [Technical Report] Paradromics completes first-in-human implant of the Connexus wireless BCI at University of Michigan (surgeons Willsey & Pandey), in a woman with motor neuron disease — the first patient in the FDA-approved Connect-One Early Feasibility Study. Device: 421 microelectrodes, chest transceiver, transcutaneous wireless link; >200 bits/sec in preclinical models. The invasive-BCI race is now a three-way contest in humans. (Paradromics Connexus first implant, Paradromics)
Jun 2026 — [Technical Report] Synchron prepares its 2026 Stentrode pivotal trial — the study it must clear to file the first-ever FDA PMA for a permanently implanted BCI. Builds on COMMAND (6 patients, no device-related SAEs over 12 months, NCT05035823) and the $200M Series D (Nov 2025). (Synchron pivotal, Synchron)

By May 2026 — [Technical Report] Neuralink scales to ≥24 patients (from 12 in Sept 2025) and broadens beyond cursor control: CONVOY (robotic-arm control — an ALS participant manipulates real objects), VOICE (speech restoration, FDA Breakthrough Device Designation, trial started Oct 2025), and Blindsight (visual-cortex vision restoration, FDA Breakthrough 2024, first trials 2026 with Cleveland Clinic Abu Dhabi; demo Apr 1 2026). $650M raised in 2025 ($9B valuation); second-gen device + automated high-volume surgery planned. (Neuralink VOICE/Blindsight/scale, Neuralink)
2026 — [Paper] Card et al. (Nature Medicine): long-term independent at-home use of an intracortical speech+cursor BCI. An ALS/dysarthria participant used the system >3,800 hours over ~2 years with no researchers present — 183,060 sentences / 1,960,163 words at 56 wpm, 92% of sentences decoded at least mostly correctly. First strong evidence of durable, unsupervised real-world speech-BCI use. (Nature Medicine — Card)

Jan 15 — [Paper] Nano-Micro Letters publishes review of non-invasive BCI with deep learning decoding and flexible bioelectronics integration. (Non-Invasive BCI)

Feb 1 — [Paper] Frontiers publishes research topic on BCI for neuroprosthetics and neurorehabilitation — motor recovery, speech restoration, neurological disorders. (BCI Neuroprosthetics)
Feb 1 — [Technical Report] Neuralink reports ~20 patients implanted in PRIME study; announces UK and UAE international trial expansion. (Neuralink PRIME)

2026 — [Technical Report] Synchron Stentrode meets primary endpoint in feasibility trial — 12-month safety and efficacy data from 6 patients. First FDA-approved permanently implanted BCI to achieve this. $200M Series D for pivotal trials. (Synchron Stentrode)
2026 — [Paper] BraIn-to-Text (BIT) framework achieves 10% word error rate for neural speech decoding (down from 24.69% SOTA). Uses contrastive learning for cross-modal alignment with audio LLMs. (BIT Framework)

Nov 2025 — [News] FDA approves Paradromics first long-term clinical trial of Connexus speech BCI. Connexus claims >200 bps information transfer rate — by their measure 20× Neuralink N1 and orders of magnitude beyond Synchron Stentrode. Three-way invasive BCI clinical race established (Neuralink, Synchron, Paradromics). (Paradromics Connexus)

Feb 1 — [Preprint] Surgical Planning Pipeline for Human Implantable BCI (medRxiv). End-to-end pipeline: pre-op imaging + vasculature mapping + target site selection + trajectory optimization. Addresses translational workflow gap. (Surgical pipeline)
Feb 4 — [Preprint] Multimodal BCI AI Decoding Review (arXiv 2502.02830). Comprehensive review unifying cross-modality mapping, sequential modeling, and fusion. Identifies multimodal Transformers as next-gen decoder architecture. (Multimodal BCI)

2026 — [Clinical] Synchron pivotal trials planned — larger patient population, controlled study design. (Synchron Stentrode)
2028-2029 — [Industry] Potential Synchron Stentrode market entry if pivotal trials succeed. (Synchron Stentrode)